Nuvalent, Inc. (NUVL)
NASDAQ: NUVL · Real-Time Price · USD
102.48
+5.76 (5.96%)
At close: Mar 31, 2026, 4:00 PM EDT
102.45
-0.03 (-0.03%)
After-hours: Mar 31, 2026, 4:01 PM EDT
Nuvalent Market Cap
Nuvalent has a market cap or net worth of $8.02 billion as of March 31, 2026. Its market cap has increased by 45.44% in one year.
Market Cap
8.02B
Enterprise Value
6.49B
1-Year Change
45.44%
Ranking
Category
Stock Price
$102.48
Market Cap Chart
Since the IPO on July 29, 2021, Nuvalent's market cap has increased from $795.96M to $8.02B, an increase of 907.45%. That is a compound annual growth rate of 63.97%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 30, 2026 | 7.60B | -2.66% |
| Dec 31, 2025 | 7.81B | 40.44% |
| Dec 31, 2024 | 5.56B | 20.68% |
| Dec 29, 2023 | 4.61B | 174.21% |
| Dec 30, 2022 | 1.68B | 82.83% |
| Dec 31, 2021 | 919.33M | 15.50% |
| Jul 29, 2021 | 795.96M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Praxis Precision Medicines | 8.22B |
| Arrowhead Pharmaceuticals | 8.21B |
| ABIVAX Société Anonyme | 8.14B |
| Bio-Techne | 8.12B |
| Axsome Therapeutics | 7.93B |
| Vaxcyte | 7.81B |
| Cytokinetics | 7.76B |
| Halozyme Therapeutics | 7.32B |